The article discusses approaches to the choice of antithrombotic therapy (AT) in patients with non-valvular atrial fibrillation (AF) and coronary heart disease (CHD) both in acute coronary syndrome (ACS) and stable forms, including those who have undergone percutaneous coronary intervention. Determination of the regimens and duration of AT depend on the form of CHD, the risk of bleeding, and the anatomy of the implanted stents in the coronary arteries. In the composition of AT in modern regulatory documents, any oral anticoagulant is recommended for patients with CHD and AF: vitamin K antagonists, direct thrombin inhibitor -dabigatran, selective factor Xa inhibitors of coagulation -rivaroxaban, apixaban
The article discusses approaches to the choice of antithrombotic therapy (AT) in patients with non-valvular atrial fibrillation (AF) and coronary heart disease (CHD) both in acute coronary syndrome (ACS) and stable forms, including those who have undergone percutaneous coronary intervention. Determination of the regimens and duration of AT depend on the form of CHD, the risk of bleeding, and the anatomy of the implanted stents in the coronary arteries. In the composition of AT in modern regulatory documents, any oral anticoagulant is recommended for patients with CHD and AF: vitamin K antagonists, direct thrombin inhibitor -dabigatran, selective factor Xa inhibitors of coagulation -rivaroxaban, apixaban
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Akhmedov B.U. | Assistant | ASMI |
| № | Ҳавола номи |
|---|---|
| 1 | 1.Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservationalResearch Program Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16(3): 308-19.2.Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events -European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16(1): 6-14.3.Fauchier L, Greenlaw N, Ferrari R, et al. Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PLoS One 2015; 10(4): e0125164.4.Bhatia GS, Lip GY. Atrial fibrillation post-myocardial infarction: frequency, consequences, and management. Curr Heart Fail Rep 2004; 1(4): 149-55.5.Schmiegelow MD, Pedersen OD, Køber L, et al. Incidence of atrial fibrillation in patients with either heart failure or acute myocardial infarction and left ventricular dysfunction: a cohort study. BMC Cardiovasc Disord 2011;11:19. |